Precigen is trading 4.45% lower at $8.16, with no specific catalyst confirmed in the available evidence.
- The company’s press-release page lists its latest announcement as the September 21 FDA platform technology designation; it shows no October 5 announcement or obvious same-day company catalyst.
- Major indexes are mixed, not moving sharply lower together, so the available market context does not establish a broad-market explanation for Precigen’s decline.